Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Scraping fibrosis: expressway to the core of fibrosis.

Literature DB >> 21546973

Scraping fibrosis: expressway to the core of fibrosis.

Wajahat Z Mehal¹, John Iredale, Scott L Friedman.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21546973 PMCID： PMC3219752 DOI： 10.1038/nm0511-552

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

12 in total

1. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.

Authors: David R Nelson; Zhengkun Tu; Consuelo Soldevila-Pico; Manal Abdelmalek; Haizhen Zhu; Yi Ling Xu; Roniel Cabrera; Chen Liu; Gary L Davis
Journal: Hepatology Date: 2003-10 Impact factor: 17.425

2. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.

Authors: Marie-Luise Berres; Rory R Koenen; Anna Rueland; Mirko Moreno Zaldivar; Daniel Heinrichs; Hacer Sahin; Petra Schmitz; Konrad L Streetz; Thomas Berg; Nikolaus Gassler; Ralf Weiskirchen; Amanda Proudfoot; Christian Weber; Christian Trautwein; Hermann E Wasmuth
Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808

3. The bone marrow functionally contributes to liver fibrosis.

Authors: Francesco P Russo; Malcolm R Alison; Brian W Bigger; Eunice Amofah; Aikaterini Florou; Farhana Amin; George Bou-Gharios; Rosemary Jeffery; John P Iredale; Stuart J Forbes
Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682

Review 4. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies.

Authors: Joel Rosenbloom; Susan V Castro; Sergio A Jimenez
Journal: Ann Intern Med Date: 2010-02-02 Impact factor: 25.391

5. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

Authors: John McHutchison; Zachary Goodman; Keyur Patel; Hala Makhlouf; Maribel Rodriguez-Torres; Mitchell Shiffman; Don Rockey; Petr Husa; Wan-Long Chuang; Robert Levine; Mark Jonas; Dickens Theodore; Richard Brigandi; Alison Webster; Margaret Schultz; Helen Watson; Britt Stancil; Stephen Gardner
Journal: Gastroenterology Date: 2010-02-13 Impact factor: 22.682

6. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Authors: Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag
Journal: N Engl J Med Date: 2008-12-04 Impact factor: 91.245

Review 7. Cellular and molecular mechanisms of fibrosis.

Authors: T A Wynn
Journal: J Pathol Date: 2008-01 Impact factor: 7.996

8. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.

Authors: Chihiro Morishima; Denise M Paschal; Chia C Wang; Christina S Yoshihara; Brent L Wood; Anthony E T Yeo; Scott S Emerson; Margaret C Shuhart; David R Gretch
Journal: Hepatology Date: 2006-03 Impact factor: 17.425

9. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC.

Authors: Alaa Melhem; Nidal Muhanna; Amal Bishara; Carlos E Alvarez; Yaron Ilan; Taiser Bishara; Amjad Horani; Mithal Nassar; Scott L Friedman; Rifaat Safadi
Journal: J Hepatol Date: 2006-02-08 Impact factor: 25.083

10. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.

Authors: Svetlana Radaeva; Rui Sun; Barbara Jaruga; Van T Nguyen; Zhigang Tian; Bin Gao
Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682

83 in total

1. Identification of RARRES1 as a core regulator in liver fibrosis.

Authors: Andreas Teufel; Diana Becker; Susanne N Weber; Steven Dooley; Katja Breitkopf-Heinlein; Thorsten Maass; Katrin Hochrath; Markus Krupp; Jens U Marquardt; Martin Kolb; Bernhard Korn; Christof Niehrs; Tim Zimmermann; Patricio Godoy; Peter R Galle; Frank Lammert
Journal: J Mol Med (Berl) Date: 2012-06-06 Impact factor: 4.599

Review 2. The Role of the Fibroblast in Inflammatory Upper Airway Conditions.

Authors: Stephen L Ball; Derek A Mann; Janet A Wilson; Andrew J Fisher
Journal: Am J Pathol Date: 2015-12-10 Impact factor: 4.307

Review 3. Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors: Johan Kreuger; Mia Phillipson
Journal: Nat Rev Drug Discov Date: 2015-11-27 Impact factor: 84.694

Review 4. Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors: Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal: Dig Dis Sci Date: 2016-07-19 Impact factor: 3.199

Review 5. Mechanisms of alveolar epithelial injury, repair, and fibrosis.

Authors: Rachel C Chambers; Paul F Mercer
Journal: Ann Am Thorac Soc Date: 2015-03

Review 6. Hepatic inflammation and fibrosis: functional links and key pathways.

Authors: Ekihiro Seki; Robert F Schwabe
Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425

7. Healing the scars of life-targeting redox imbalance in fibrotic disorders of the elderly.

Authors: Anke Liepelt; Frank Tacke
Journal: Ann Transl Med Date: 2015-05

Review 8. Interleukin-17: Friend or foe in organ fibrosis.

Authors: Kritika Ramani; Partha S Biswas
Journal: Cytokine Date: 2019-02-14 Impact factor: 3.861

Review 9. Antifibrotic therapies in the liver.

Authors: W Z Mehal; D Schuppan
Journal: Semin Liver Dis Date: 2015-05-14 Impact factor: 6.115

10. Targeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis.

Authors: Zhongwei Cao; Tinghong Ye; Yue Sun; Gaili Ji; Koji Shido; Yutian Chen; Lin Luo; Feifei Na; Xiaoyan Li; Zhen Huang; Jane L Ko; Vivek Mittal; Lina Qiao; Chong Chen; Fernando J Martinez; Shahin Rafii; Bi-Sen Ding
Journal: Sci Transl Med Date: 2017-08-30 Impact factor: 17.956